Rodríguez PJM, Díaz RYV, Rojas RY, Rodríguez BY, Núñez AE

Language: Spanish
References: 34
Page: 546-557
PDF size: 271.20 Kb.

ABSTRACT

Huntington Disease is a neurodegenerative disorder transmitted as an autosomal dominant trait. Selective neuronal loss in the striatum leads to chorea and cognitive impairment. It is a progressive disease with onset in midlife, which chronically evolves over many years and for which no curative treatment is available today. A review on the 547 current knowledge of Huntington Disease was carried out. Etiopathogenic, clinical, diagnostic methods and treatment options were included.

REFERENCES

1. Fahn S, Jankovic J. Huntington disease. En: Principles and practice of movement disorders. Philadelphia: Editorial Churchil livingstone Elsevier; 2007.p.369-85.

2. Wild EJ, Tabrizi SJ. The differential diagnosis of Chorea. Practical Neurol. 2007; 7:360-373.

3. Arbor A, De Jong RN. George Huntington (1850-1916). En: The Founders of Neurology. 2ª ed. Illinois: Ed. Springfield Charles C Thomas Pub; 1970.p. 453-6.

4. Walker FO. Huntington’s disease. Lancet. 2007; 369: 218-28.

5. Vázquez Sánchez F, Rodríguez Martínez E, Arés Luque A. Actualización en coreas. Rev Neurol. 2009;48: 11-16.

6. Biglan KM, Shoulson I. Huntington’s disease. En: Hallett M, Poewe W. Therapeutics of Parkinson’s Disease and Other Movement Disorders. Chicester: Editorial John Wiley & Sons; 2008.p.295–315.

7. Velázquez Pérez L, Rodríguez Labrada R. Características generales de las enfermedades poliglutamínicas. En: Manifestaciones tempranas de la Ataxia espinocerebelosa tipo 2. Holguín: Ediciones Holguín; 2012.p.11-32.

8. Huntington's disease Collaborative Research Group. A novel gen containg a trinucleotide repeats that is expanded and instable on Huntington's disease chromosoma.Cel.1993; 72:971-83.

9. Azzarelli A. Enfermedad de Huntington y degeneraciones de algunos núcleos subcorticales. En: Neuropatología, diagnóstico y clínica. Barcelona: Editorial Edisma; 2000.p. 603-20.

10. Landles C, Bates G. Huntingtin and the molecular pathogenesis of Huntington disease. EMBO. 2004;5:958-963.

11. Kremer B, Almqvist E, Theilmann J. Sex-dependent mechanisms for expansions and contractions of the CAG repeat on affected Huntington disease chromosomes. Am J Hum Genet.1995; 57:343–350.

12. Wexler NS, Lorimer J, Porter J. Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington’s disease age of onset. Proc Natl Acad Sci. 2004;101: 3498–3503.

13. Brocklebank D, Gayan J, Andresen JM. Repeat instability in the 27–39 CAG range of the HD gene in the Venezuelan kindreds: counseling implications. Am J Med Genet B Neuropsychiatr Genet.2009;150:425–429.

14. Rosales Reynoso MA, Barros Núñez P. Biología molecular y Medicina. Diagnóstico molecular de la enfermedad de Huntington. Gac Méd Méx. 2008; 144(3):271-3.

15. Potter NT, Spector EB, Prior TW. Technical standars and guidelines for Huntington disease testing. Genet Med. 2004; 6:61-65.

16. Ravina B, Romer M, Constantinescu R. The relationship between CAG repeat length and clinical progression in Huntington’s disease. Mov Disord. 2008; 23:1223–1227.

17. Ross RA, Vegtervan der Vlis M, Hermans J, Elshove HM, Moll AC, Van de Kamp JJ, et al. Age at onset in Huntington's disease: effect on line of inherintance and patient's sex. Nat Genet.1993; 28:515-9.

18. Vonsattel JP, Myers RH, Stevens TJ, Ferrante RJ, Bird ED, Richardson EP. Neuropathological classification of Huntington’s disease. J Neuropathol Exp Neurol. 1985; 44:559–577.

19. Vonsttel JP, Keller C, Del Pilar Amaya M. Neuropathology of Huntington’s disease. En: Vinken PJ, Bruyn GW. Handbook of Clinical Neurology. Amsterdam: Editorial Elsevier; 2008.p. 599–618.

20. Aucoin JS, Jiang P, Aznavour N. Selective cholinergic denervation, independent from oxidative stress, in a mouse model of Alzheimer’s disease. Neuroscience. 2005; 132:73–86.

21. Penney JB, Young AB. Striatal inhomogeneities and basal gan-glia function. Mov Disord. 1986;1:3–15.

22. Albin RL, Qin Y, Young AB, Penney JB, Chesselet MF. Preproenkephalin messenger RNA-containing neurons in striatum of patientswith symptomatic and presymptomatic Huntington’s disease: an in situ hybridization study. Ann Neurol.1991; 30:542–549.

23. Albin RL, Reiner A, Anderson KD. Preferential loss of striato-external pallidal projection neurons in presymptomatic Huntington’s disease. Ann Neurol. 1992;31:425–430.

24. Jankovic J. Movement Disorders. En: Bradley WG, Daroff RB, Fenichel GM, Jankovic J, Mazziotta JC. Bradley’s Neurology in Clinical Practice. Philadelphia: Editorial Elsevier Saunders; 2012.p. 1762-1801.

25. Ropper AH, Samuels A. Degenerative Diseases of the Nervous System En: Adams & Victors' Principles of Neurology. 9 ed. Philadelphia: Ed. McGraw-Hill; 2009.p.895-954.

26. Tibben A, Duivenvoorden HJ, Vegter-van der Vlis M. Presymptomatic DNA testing for Huntington disease: identifying the need for psychological intervention. Am J Med Genet. 1993; 48:137–144.

27. Wild EJ, Mudanohwo EE, Sweeney MG, Schneider SA, Beck J, Bhatia KP, et al. Huntington’s disease phenocopies are clinically and genetically heterogeneous. Mov Disord. 2008; 23: 716-20.

28. Hersch SM, Rosas HD. Neuroprotection for Huntington’s disease: ready, set, slow. Neurotherapeutics. 2008;5: 226-36.

29. Mestre T, Ferreira J, Coelho MM, Rosa M, Sampaio C. Therapeutic interventions for disease progression in Huntington’s disease. Cochrane Database Syst. 2009[citado 25 jun 2013]; 8(3)

30. Huntington Study Group. Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurol. 2006; 66:366–372.

31. Adam OR, Jankovic J. Symptomatic treatment of Huntington disease. Neurotherapeutics. 2008; 5: 181-97.

32. Hyson HC, Kieburtz K, Shoulson I. Safety and tolerability of high-dosage coenzyme Q10 in Huntington’s disease and healthy subjects. Mov Disord. 2010;25:1924–1928.

33. Shoulson I, Young AB. Milestones in Huntington Disease. Mov Disord. 2011; 26(6):1127-1133.

34. Discapnet. (sede web). Enfermedad de Huntington. España: Fundación ONCE; 2009 [27 jun 2013].